Raleigh, NC (PRWEB) April 18, 2012
Arbovax, a Raleigh based Bio-Technology Company won a prestigious ViE award at the World Vaccine Congress 2012 in Washington DC. Arbovax has developed the only whole virus vaccine targeted to treat insect borne diseases such as Dengue Fever, West Nile, Japanese Encephalitis and Chikungunya. Their whole virus vaccine approach has attracted attention following a report issued last week in the Proceedings of National Academy of Science that human antibodies which neutralize the virus bound to a complex structure was only present on a completely assembled dengue virus. The authors of the study team of scientists from the University of North Carolina at Chapel Hill and Vanderbilt University found similar behaviors in the HIV and West Nile Virus.
“We have long been saying that whole virus vaccines are the most effective way to address insect-borne viral diseases” said Malcolm Thomas, CEO of Arbovax, he added “it is extremely gratifying to see an independent group come to the same conclusions from a different perspective”
Arbovax is currently developing vaccines against Dengue Fever and Chikungunya using their ‘host-range mutation’ whole virus approach, based on technology originally discovered by two professors at NC State University. The company recently completed successful animal trials on a Chikungunya vaccine candidate.